It is uncertain if different immunomodulatory drugs (IMID) pose distinct thrombotic risk in patients with newly diagnosed
Abstract
It is uncertain if different immunomodulatory drugs (IMID) pose distinct thrombotic risk in patients with newly diagnosed multiple myeloma (MM). Among 2397 MM patients from the SEER-Medicare database from 2007 to 2013, 78% received lenalidomide, and 22% received thalidomide. After inverse probability weighting to balance confounders, the 12-month incidences of venous thromboembolism (VTE 10%) and arterial thromboembolism (ATE 5%) were similarly high in both groups. Lenalidomide versus thalidomide had a subdistribution hazard ratio of 1.11 (0.59-2.02) for VTE and a subdistribution hazard ratio of 0.96 (0.45-1.98) for ATE. Overall survival was not significantly different with a hazard ratio of 0.88 (0.60-1.18) for lenalidomide versus thalidomide. Concurrent anticoagulant prophylaxis was infrequently prescribed in < 20% of both groups. Our study demonstrates that despite improvement in myeloma-directed therapy and supportive care, thrombosis remains an important consideration for all IMID-treated MM patients. Appropriate risk stratification and vigilant thromboprophylaxis remain essential to prevent this complication.
PMID: 31773215 [PubMed - indexed for MEDLINE]
15:43
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
15:43
In reply to this message
pubmed: caandvteortroorpul
Breast cancer and recurrent thrombosis - Results from prospective single center study.
//www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--media.wiley.com-assets-7388-69-wiley-full-text.png Related Articles
Breast cancer and recurrent thrombosis - Results from prospective single center study.
Breast J. 2019 07;25(4):783-785
Authors: Kovac M, Kovac Z, Tomasevic Z, Tomic B, Gvozdenov M, Radojkovic D
PMID: 31079419 [PubMed - indexed for MEDLINE]
16 January 2020
12:16
Cancer & Heart (Cardio-Oncology, Cardiotoxicity, TEV)
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
12:16
In reply to this message
pubmed: caandvteortroorpul
Comparison between direct factor Xa inhibitors and low-molecular-weight heparin for efficacy and safety in the treatment of cancer-associated venous thromboembolism: A meta-analysis.
Comparison between direct factor Xa inhibitors and low-molecular-weight heparin for efficacy and safety in the treatment of cancer-associated venous thromboembolism: A meta-analysis.
J Cancer Res Ther. 2019;15(7):1541-1546
Authors: Yang M, Li J, Sun R, Wang Y, Xu H, Yang B, Wu X, Yu L
Comments
Post a Comment
اكتب تعليق حول الموضوع